Morphosys’ statement came after a report that cited two people familiar with the matter, of a safety issue with its experimental drug pelabresib, which is being developed to treat myelofibrosis, a rare type of blood cancer affecting the bone marrow.
Tag Archive for: Morphosys
Novartis announced Thursday an exclusive strategic partnership with Arvinas to advance an oral protein degrader for prostate cancer, while also announcing the tender offer for its $2.9 billion acquisition of MorphoSys has commenced.
The Swiss pharma’s dealmaking momentum continues in early 2024 with the acquisition of German biotech MorphoSys in an effort to strengthen its oncology portfolio.
A review of the latest executive moves in the pharma industry over the past several months.
With $120 million in backing, Human Immunology Biosciences (HI-Bio) launched two assets licensed from MorphoSys AG aimed at severe immune-mediated diseases.
Merck veteran Fiona H. Marshall has been tapped as president of the Novartis Institutes for BioMedical Research (NIBR). She takes over from Jay Bradner, who will leave the company effective Oct. 31.